Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Ann Oncol. 2019 Dec 1;30(12):2013-2014. doi: 10.1093/annonc/mdz237.
No abstract available

Publication types

  • Published Erratum